| 0.547249 -0.003 (-0.5%) | 04-26 15:57 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.72 | 1-year : | 0.84 |
| Resists | First : | 0.61 | Second : | 0.72 |
| Pivot price | 0.48 |
|||
| Supports | First : | 0.48 | Second : | 0.4 |
| MAs | MA(5) : | 0.51 |
MA(20) : | 0.49 |
| MA(100) : | 0.46 |
MA(250) : | 0.6  |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 70 |
D(3) : | 61.8 |
| RSI | RSI(14): 57.4 |
|||
| 52-week | High : | 1.33 | Low : | 0.34 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ VTAK ] has closed below upper band by 14.8%. Bollinger Bands are 16.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.6 - 0.6 | 0.6 - 0.61 |
| Low: | 0.52 - 0.52 | 0.52 - 0.53 |
| Close: | 0.54 - 0.55 | 0.55 - 0.55 |
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.
Wed, 24 Apr 2024
Catheter Precision, Inc. (VTAK) Announces Receipt of First Purchase Order for LockeT from HCA Healthcare Facility - Yahoo Finance
Thu, 18 Apr 2024
Medical Device Innovator Catheter Precision Inc. (NYSE American: VTAK) Gains Momentum with LockeT and VIVO ... - Financial Content
Fri, 26 Jan 2024
Catheter Precision Converts Preferred Stock to Common Shares - TipRanks.com - TipRanks
Mon, 22 Jan 2024
Catheter Precision, Inc. (NYSE American:VTAK) Presenting at the Sequire Investor Summit in Puerto Rico - Fort Worth Star-Telegram
Mon, 22 Jan 2024
Catheter Precision, Inc. (VTAK) Secures New Distributor in Brazil for LockeT - Raleigh News & Observer
Wed, 17 Jan 2024
Catheter Precision's VIVO System Featured in Electrophysiology Publication - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 4.6e+006 (%) |
| Held by Institutions | 33.3 (%) |
| Shares Short | 58 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.62e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -12 % |
| Return on Assets (ttm) | 232.9 % |
| Return on Equity (ttm) | -47.9 % |
| Qtrly Rev. Growth | 90000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -37 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 27860 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|